Results of the Company's Annual General Meeting 2025
All of the resolutions were passed as ordinary resolutions. A copy of the poll results for the AGM, along with the Notice of AGM, is available on the AngloGold Ashanti website at www.anglogoldashanti.com.
1.
Votes 'for' include those votes giving the Chair discretion.
2.
For all relevant purposes votes which are 'withheld' or 'abstained' are not votes in law and are not counted in the calculation of the proportion of votes for and against each resolution.
Expand
On 4 April 2025, the record date as set out in the Notice of AGM, there were 504,087,287 ordinary shares in issue. Shareholders are entitled to one vote per share on a poll.
Corporate update
Further to the announcement made on 20 December 2024, the Company confirms that Rhidwaan Gasant has stepped down from the Board on 27 May 2025. Other than fees accrued up to the date he ceased to be a director, no other remuneration payment will be made by the Company to Rhidwaan Gasant after he ceases to be a non-executive director, nor will any payment for loss of office be made.
The previously announced appointment of Alan Ferguson as Lead Independent Director and Diana Sands as Chair of the Audit and Risk Committee also took effect on 27 May 2025.
JSE Sponsor: The Standard Bank of South Africa Limited
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
11 hours ago
- Business Wire
EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ('Edgewise' or 'the Company') (NASDAQ: EWTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Edgewise reported data from the clinical trials on its drug candidate sevasemten on June 26, 2025. The Company claimed the results were positive but also disclosed that the FDA had "deemed the CANYON data alone insufficient for an accelerated approval." Based on this news, shared of Edgewise fell by 8.86% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
16 hours ago
- Business Wire
ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Altimmune, Inc. ('Altimmune' or 'the Company') (NASDAQ: ALT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Altimmune announced "topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH)," on June 26, 2025. Although the Company characterized the results as 'positive,' it added that 'the effects on fibrosis improvement without worsening of MASH in an ITT analysis were 31.8% and 34.5% for pemvidutide 1.2 mg and 1.8 mg, respectively compared with 25.9% for placebo (differences not statistically significant)." Based on this news, shares of Altimmune fell by 52.18% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
16 hours ago
- Business Wire
UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. ('Unicycive' or 'the Company') (NASDAQ: UNCY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Unicycive announced on June 30, 2025, that the FDA 'has issued a CRL [Complete Response Letter] for its New Drug Application (NDA) for OLC to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis." The Company added that "After submitting the NDA, and as a part of the application review and routine information requests, the FDA notified Unicycive that a third-party manufacturing vendor of its main contract development and manufacturing organization (CDMO) was cited for deficiencies following a cGMP inspection." Based on this news, shares of Unicycive fell by 29.85% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
